A phase I trial evaluating the safety and immunogenicity of a candidate tuberculosis vaccination regimen, ChAdOx1 85A prime – MVA85A boost in healthy UK adults

Background This phase I trial evaluated the safety and immunogenicity of a candidate tuberculosis vaccination regimen, ChAdOx1 85A prime-MVA85A boost, previously demonstrated to be protective in animal studies, in healthy UK adults. Methods We enrolled 42 healthy, BCG-vaccinated adults into 4 groups: low dose Starter Group (n = 6; ChAdOx1 85A alone), high dose groups; Group A (n = 12; ChAdOx1 85A), Group B (n = 12; ChAdOx1 85A prime – MVA85A boost) or Group C (n = 12; ChAdOx1 85A – ChAdOx1 85A prime – MVA85A boost). Safety was determined by collection of solicited and unsolicited vaccine-related adverse events (AEs). Immunogenicity was measured by antigen-specific ex-vivo IFN-γ ELISpot, IgG serum ELISA, and antigen-specific intracellular IFN-γ, TNF-α, IL-2 and IL-17. Results AEs were mostly mild/moderate, with no Serious Adverse Events. ChAdOx1 85A induced Ag85A-specific ELISpot and intracellular cytokine CD4+ and CD8+ T cell responses, which were not boosted by a second dose, but were boosted with MVA85A. Polyfunctional CD4+ T cells (IFN-γ, TNF-α and IL-2) and IFN-γ+, TNF-α+ CD8+ T cells were induced by ChAdOx1 85A and boosted by MVA85A. ChAdOx1 85A induced serum Ag85A IgG responses which were boosted by MVA85A. Conclusion A ChAdOx1 85A prime – MVA85A boost is well tolerated and immunogenic in healthy UK adults.

Background: This phase I trial evaluated the safety and immunogenicity of a candidate tuberculosis vaccination regimen, ChAdOx1 85A prime-MVA85A boost, previously demonstrated to be protective in animal studies, in healthy UK adults. Methods: We enrolled 42 healthy, BCG-vaccinated adults into 4 groups: low dose Starter Group (n = 6; ChAdOx1 85A alone), high dose groups; Group A (n = 12; ChAdOx1 85A), Group B (n = 12; ChAdOx1 85A prime -MVA85A boost) or Group C (n = 12; ChAdOx1 85A -ChAdOx1 85A prime -MVA85A boost). Safety was determined by collection of solicited and unsolicited vaccine-related adverse events (AEs). Immunogenicity was measured by antigen-specific ex-vivo IFN-c ELISpot, IgG serum ELISA, and antigen-specific intracellular IFN-c, TNF-a, IL-2 and IL-17. Results: AEs were mostly mild/moderate, with no Serious Adverse Events. ChAdOx1 85A induced Ag85Aspecific ELISpot and intracellular cytokine CD4+ and CD8+ T cell responses, which were not boosted by a second dose, but were boosted with MVA85A. Polyfunctional CD4+ T cells (IFN-c, TNF-a and IL-2) and IFN-c+, TNF-a+ CD8+ T cells were induced by ChAdOx1 85A and boosted by MVA85A. ChAdOx1 85A induced serum Ag85A IgG responses which were boosted by MVA85A.

Background
Tuberculosis (TB) is now the leading single infectious disease killer in the world despite an annual 2% reduction in TB worldwide. In 2017, an estimated 1.6 million people died from TB, with 10 million new cases throughout the world [1]. The End TB strategy of global eradication of TB seeks to address this pressing issue, and one of the most valuable tools for its success is the development of a safe and effective TB vaccine [1].
The only licenced TB vaccine, Bacille Calmette-Guérin (BCG), is highly effective at preventing TB meningitis and disseminated disease in children. However, the lack of consistent protection against adult pulmonary TB means a more universally effective vaccine is urgently needed. Subunit vaccines to boost the efficacy of BCG allow the retention of the protective benefits against systemic disease [2][3][4][5]. Recombinant viral vectors have shown early promise in animal and human studies [6][7][8][9][10], however the first efficacy trial with recombinant Modified Vaccinia virus Ankara (MVA85A) expressing the highly conserved, immunodominant, Mycobacterial antigen 85A (Ag85A) did not confer additional protection over BCG alone in South African infants [11]. This was likely in part due to reduced immunogenicity seen in this setting. More potent regimens are therefore needed. Heterologous 'prime-boost ' [12,13]. A recombinant adenoviral vaccine candidate, AERAS-402, has been evaluated as a prime-boost regimen with MVA85A in a phase I clinical trial in healthy BCG-vaccinated UK adults. This heterologous prime-boost regime was well-tolerated and induced increased frequency of antigen-specific CD4+ and CD8+ T-cell responses [14]. Recently, a protein adjuvanted subunit vaccine M72, conferred 54% protection against TB disease in M.tb latently infected subjects [15].
ChAdOx1 85A is a novel chimpanzee adenoviral vectored vaccine expressing Ag85A. An advantage of simian adenoviral vectors over human adenoviral vectors is the low prevalence of preexisting anti-vector antibodies in humans, a factor limiting the use of adenoviruses to date [16]. The vector, ChAdOx1, expressing two influenza antigens, NP and M1, has previously been evaluated in a small phase I dose escalation trial and was found to be safe and immunogenic [17]. Preclinical murine studies have demonstrated ChAdOx1 85A to be consistently protective when used as part of a BCG-ChAdOx1 85A-MVA85A immunisation regime [18]. The aim of this first-in-human experimental medicine trial was to evaluate the safety and immunogenicity of ChAdOx1 85A, alone and as a prime-boost regime with MVA85A in healthy, BCG-vaccinated UK adults.

Trial design
We conducted a phase I, open label, dose escalation clinical trial in 42 BCG-vaccinated UK adults. All trial documents were approved by the Medicines and Healthcare Regulatory Agency (MHRA, EudraCT 2012-005118-21) and South Central -Oxford A Research Ethics Committee (reference: 13/SC/0098). It was registered with clinicaltrials.gov (ref NCT01829490) and conducted according to the principles of the Declaration of Helsinki and Good Clinical Practice.

Participants
Volunteers were recruited from the Oxford and Birmingham area, providing written informed consent prior to screening. Visits occurred at the Centre for Clinical Vaccinology and Tropical Medicine (CCVTM), Oxford, and the NIHR Wellcome Trust Clinical Research Facility, Birmingham (NIHR WTCRF). All vaccination visits were at the CCVTM. Volunteers were healthy, aged between 18 and 55, and had received BCG vaccination from an independent source prior to screening (no less than 6 months prior to date of enrolment). Baseline biochemical and haematological analysis, serological testing for HIV, hepatitis B and hepatitis C were performed to ensure no abnormalities warranting exclusion. Latent Mycobacterium tuberculosis (M.tb) infection (LTBI) was excluded at screening with a negative IFN-c release assay response to ESAT-6 and CFP-10, by means of the T Spot.TB kit (Oxford Immunotec, UK) or QuantiFERON Ò -TB Gold In-Tube. The full inclusion and exclusion criteria are in Supplementary Methods 1.

Vaccines
ChAdOx1 85A (lot no. 02N12-01) was constructed under Good Manufacturing Practice (GMP) conditions at the Clinical Biomanufacturing Facility (CBF), University of Oxford, UK [16]. MVA85A (lot no. 0050811) was constructed as previously documented [18], and produced under GMP conditions by IDT Biologika GmbH (IDT), Germany. Both vaccines were stored prior to use at the CCVTM in a secure locked, monitored À80°C freezer. Both vaccines were administered intramuscularly in the deltoid region of the arm.

Clinical interventions
Six volunteers were enrolled into the Starter Group and received ChAdOx1 85A at a dose of 5 Â 10 9 virus particles (vp) on day 0 (D0), a safety review was performed 48 h following vaccination of the first volunteer before vaccination of the subsequent five volunteers. A safety review was performed once all volunteers in this group had reached D14 to ensure no safety concerns before proceeding to the predicted optimal dose of ChAdOx1 85A based on the previous Flu study [17]. After successful safety review, the first Group A volunteer received ChAdOx1 85A at a dose of 2.5 Â 10 10 vp with safety review 48 h later. No safety concerns were raised, and a further 23 volunteers were randomised to Group A (ChAdOx1 85A 2.5 Â 10 10 vp at D0) or Group B (ChAdOx1 85A 2.5 Â 10 10 vp at D0 with MVA85A 1 Â 10 8 plaque forming units (pfu) boost at D56) using sequentially numbered, sealed envelopes prepared by an independent statistician and opened by the trial clinician at the time of volunteer enrolment. Following our previous trial results, where two doses of AERAS-402 followed by MVA85A was the most potent regime for the induction of antigen-specific CD8+ T cell responses [14], we added Group C, whereby 12 volunteers were enrolled to receive two doses of ChA-dOx1 85A 2.5 Â 10 10 vp (D0 and D28) with MVA85A 1 Â 10 8 pfu boost at D119.
All volunteers had a clinical review 30 and 60 min following vaccination. Expected local and systemic solicited and unsolicited adverse events (AEs) were collected by volunteers using a 7-day diary-card, and reviewed by the clinical team at follow-up visits along with vital signs. Starter Group and Group A were followedup at: D2, D14, D28, D56, D84 and D168, Group B: D2, D14, D28, D56, D58, D63, D84, D140 and D224, and Group C: D2, D14, D28, D30, D42, D56, D119, D121, D126, D147, D203 and D287. Solicited and unsolicited AEs were graded mild, moderate or severe. Assignment of causality was conducted according to a pre-defined criteria specified in the protocol. Safety bloods were taken 14 days following ChAdOx1 85A and 7 days following MVA85A, with bloods also taken on the day of 2nd and 3rd vaccinations depending on the individual volunteer schedule. Blood for exploratory immunology was taken at all visits.

Whole blood intracellular cytokine staining (WB ICS)
WB cytokine responses were measured in samples collected at D0, D14 and D168 (Group A); D0, D14, D56, D63 and D224 (Group B); and D0, D14, D28, D42, D119, D126 and D203 (Group C). The assay was performed on fresh samples as previously described [19]. Briefly, 500 ml WB was added to duplicate tubes containing either a pool of Ag85A peptides (66 15mer peptides, overlapping by 10 amino acids) at a final concentration of 2ug/ml, SEB at a final concentration of 5ug/ml (positive control) or tubes containing no antigen (negative control). The co-stimulatory antibodies a-CD28 and a-CD49d were added to each tube at a final concentration of 0.5 mg/ml and tubes were then incubated at 37°C, 5% CO 2 for 5 h before Brefeldin A was added at a final concentration of 5ug/ml. Tubes were then incubated at 37°C in a water bath timed to switch off after 6 h. The following morning, 50ul 20 mM EDTA was added to each tube and incubated at room temperature for 15 mins. Duplicate tubes were then added to 9 ml FACS lysing solution (BD Bioscience) and incubated at room temperature in the dark for 10 mins before centrifuging at 1500 rpm for 7 mins. Supernatant was discarded and cell pellet washed in 10 ml PBS and centrifuged at 1500 rpm for 7 mins. Supernatant was discarded and the cell pellet resuspended in 1 ml PBS with 10% DMSO and transferred to a cryovial for freezing and batched analysis at the end of the trial.
The assay was performed in triplicate with serum diluted 1:10 in Casein blocking buffer (Sigma). Serum pooled from five high IgG responders was the positive control with serum from BCGnaïve individuals as negative control. Goat anti-human c-chain whole IgG alkaline phosphatase conjugate (Sigma Aldrich) was used for capture of bound serum IgG. pNPP substrate (Sigma) was used for detection of IgG and the reaction stopped with 3 M NaOH. Absorbance was measured at 405 nm. Mean optical density (OD) of triplicate blank wells were subtracted from mean OD of test sample triplicate.

Statistical analysis
Safety was assessed by analysing frequency and severity of vaccine related local and systemic, solicited and unsolicited AEs, and summarised by frequency and severity of AEs using descriptive statistics. Baseline demographics, AEs, ELISpot, WB ICS and antibody data were analysed using GraphPad Prism. One way ANOVA was used to detect differences in baseline demographics across groups. The Mann Whitney U test was used to detect differences between groups, the Kruskal-Wallis test was used for looking at differences between more than two groups and the Wilcoxon matched-pairs signed rank test was used for differences between time points within the same group. Area Under the Curve (AUC) analysis was used to detect difference over time.

Results
Between 22nd July 2013 and 30th June 2015, 42 volunteers were enrolled ( Fig. 1 Consort diagram). One volunteer in Group C withdrew prior to their final visit; all data prior to the point of withdrawal were included in analysis. Baseline demographics including age, sex and time between BCG and enrolment, were comparable between groups (Supplementary Table 1).

Vaccine safety
There were no safety concerns in the Starter Group. Local and systemic AEs were expected and mild in nature (Table 1). Volunteers enrolled in Groups A, B and C reported expected local AEs, the majority of which were mild/moderate in nature (Table 1). Two volunteers in Group B reported severe pain at vaccination site following MVA85A vaccination at D56. Local redness and swelling across all vaccinations were comparable with no significant difference seen (p > 0.05) (Supplementary Fig. 2). The majority of systemic, solicited AEs were also mild to moderate in nature. Of those who reported a severe systemic AE (n = 4); one volunteer in Group A reported severe fatigue, feverishness and headache, and one in Group B reported severe feverishness and fatigue, all following D0 ChAdOx1 85A. One Group B volunteer reported severe feverishness, myalgia and malaise following MVA85A, and a second volunteer, also in Group B reported severe headache.
Frequency of unsolicited AEs, including abnormalities of blood safety profile, considered to be related to vaccination are included in Table 1. A volunteer in Group A reported transient axillary lymphadenopathy. There were 9 haematological AEs considered to be related to ChAdOx1 85A vaccination (lymphopaenia (3 mild), neutropaenia (1 mild, 1 moderate), leukopaenia (1 mild), eosinophilia (2 mild) and thrombocytopaenia (1 mild)) and 5 related to MVA85A (lymphopaenia (1 mild, 1 moderate), leukopaenia (2 mild) and eosinophilia (1 mild)). One volunteer in Group C had a moderate lymphopaenia considered possibly related to MVA85A which was ongoing at the end of the study. All others resolved fully.
A Group C volunteer reported shingles in the T9 dermatomal distribution at D56, 28 days post D28 vaccination with ChAdOx1 85A. Due to the timing of the event and past medical history (volunteer had experienced two previous episodes of shingles several years prior to enrolment) this was deemed not related to vaccination.
There were no Serious Adverse Events (SAEs) reported during the course of the study in any group.  2I; p = 0.0005 for Groups A, B and C), and remained significantly higher than baseline until the end of follow-up (D168 in Group A (p = 0.003). A second dose of ChAdOx1 85A (Group C) did not further boost these responses (Fig. 2I), however they were significantly boosted with MVA85A vaccination at D56 and D119 in Group B and Group C volunteers respectively (p = 0.0005 for Group B D63 and p = 0.001 for Group C D126, (Fig. 2I)) remaining significantly above baseline at the end of the study (Group B D224 p = 0.0005; for; Group C D287 p = 0.001). No difference was detected in the magnitude of the MVA85A-boosted responses between Group B and Group C one week post-MVA85A (p = 0.2274).
AUC analysis for Ag85A-specific responses was performed on groups B and C and volunteers from a previous trial, TB022, who received MVA85A alone by intramuscular injection [20]. To account for the different time points in the groups, analysis was only performed using four time points, starting from 1 week post-MVA85A vaccination and including 4, 12 and 24 weeks post-MVA85A vaccination. Groups B and C had a median AUC of 14985 and 14978 SFC/1 Â 10 6 PBMC respectively, compared with 9527 SFC/1 Â 10 6 PBMC in the MVA85A alone group, although the difference between the groups was not significant.
An increase in Ag85A-specific responses was detected in the Starter Group but did not reach statistical significance. AUC analysis comparing the Starter Group with Group A was not significant Baseline PPD-specific IFN-c responses were not boosted by ChAdOx1 85A in the Starter Group or groups A and C, however group B had a significant increase in responses between D0 and D14 (p = 0.007) (Supplementary Table 2). Boosting with MVA85A significantly increased PPD-specific IFN-c responses at D63 in Group B (p = 0.005) and D126 in Group C (p = 0.002), contracting to baseline at D84 and D147 (Groups B and C respectively). MVA85A boosted responses were not significantly different in Group B (D63) and Group C (D126).
ChAdOx1-specific responses were detected in Groups A, B and C (Fig. 2II) peaking at D14 (Group A p = 0.0015; Group B p = 0.0005; Group C p = 0.0278). Group A remained significantly higher until D28 (p = 0.027), Group B until D56 (p = 0.005) and Group C until D119 (p = 0.024). A second dose of ChAdOx1 85A (Group C) did not enhance this anti-vector specific response.
No MVA-specific responses were detectable in Starter Group and Group A. Group B and C had significantly higher responses to the MVA CD8+ T cell epitopes one week following MVA85A vaccination (Group B p = 0.034; Group C p = 0.0098). Responses to CD4+ T cell epitopes were detectable in Group B, one and four weeks post-MVA85A vaccination (p = 0.033 and p = 0.012 respectively) (Fig. 2III).
There was no statistical association between ELISpot insert and vector responses: For ChAdOx1 vs Ag85A at D14 for Groups A, B and C combined and at D42, following a second ChadOx1 85A dose,   Ag85A-specific IFN-c+, TNF-a+ CD8+ T cells were induced by ChAdOx1 85A vaccination (Fig. 3II) and were boosted by MVA85A (Group B: D63 p = 0.008; Group C: D126 p = 0.019). These responses were higher in group C than in group B (p = 0.0007) and remained significantly higher at the end of the follow-up for both groups (Group B: D0 vs D224 p = 0.01; Group C: D0 vs D203 p = 0.001).

Immunoglobulin G (IgG) responses following ChAdOx1 85A and MVA85A vaccination
Ag85A-specific IgG responses were induced by 5 Â 10 9 vp ChA-dOx1 85A, peaking at D28 and remaining higher than baseline at D168 (Starter Group p = 0.031 for all time points). A similar pattern was observed with 2.5 Â 10 10 vp ChAdOx1 85A, with responses being significantly higher at D14 than D0 (p = 0.0005 for all time points up to D84 and p = 0.001 at D168 (Group A), P = 0.0005 up to D140 and p = 0.002 for D224 (Group B) and p = 0.0005 for all time points in Group C up to D147 and p = 0.001 for D287. The magnitude of the measured IgG response was not ChAdOx1 85A dose-dependent ( Supplementary Fig. 3I). Boosting with MVA85A resulted in increased IgG fold change in Group B at D84 (D84 v D14 p = 0.009; D84 v D28 p = 0.005 and D84 v D56 p = 0.0005) and Group C at D147 (D147 v D14 p = 0.001; D147 v D28 p = 0.002; D147 v D42 p = 0.024, D147 v D56 p = 0.0098 and D147 v D119 p = 0.001). Boosting with ChAdOx1 85A at D28 enhanced the IgG fold change in Group C (p = 0.001 at D42) (Fig. 5I). Ag85A-specific IgG responses were not significantly different between Groups B and C (p > 0.05 at 1 and 4 weeks post-MVA85A vaccination) ( Supplementary Fig. 3I and Fig. 5I).
Vaccination with 5 Â 10 9 vp ChAdOx1 85A induced significant ChAdOx1-specific IgG in the Starter Group (p = 0.031 at D56 and D84). ChAdOx1 85A at a dose of 2.5 Â 10 10 vp induced significant ChAdOx1-specific IgG in Groups A, B and C (Group A p = 0.0005 at D14 up to D84 and p = 0.001 at D168; Group B p = 0.001 at D14, p = 0.0005 at D28 up to D140 and p = 0.002 at D224; Group C p = 0.02 at D14, p = 0.012 at D28, p = 0.0005 at D42 up to D147) ( Supplementary Fig. 3II). Vaccine-induced anti-ChAdOx1 IgG fold change was significant in Groups B and C. The induced ChAdOx1 response was significantly higher at D63 and remained high up to D140 in Group B (D63 p = 0.021; D84 p = 0.027 and D140 p = 0.007 all compared to D14). Significantly higher fold change IgG response was observed at all time points up to D147 compared to D14 in Group C (D28 p = 0.016, D56 p = 0.001 and p = 0.0005 for all other time points up to D147). Two doses of ChA-dOx1 85A induced higher fold change in Group C (D28 vs D56 peak fold change p = 0.0005; Fig. 5II).
MVA85A vaccination induced anti-MVA IgG that peaked two weeks after vaccination and remained significantly higher than D0 in both Groups B (D63 p = 0.005; D84 and D140 p = 0.0005 and D224 p = 0.002) and Group C (D126 p = 0.002, D147 p = 0.0005 and D287 p = 0.001) (Supplementary Fig. 3III). Fold change MVA-specific IgG response was significantly induced in both Groups B and C (p = 0.0005 for D84 and D140 Group B and D147 Group C; p = 0.002 for D224 Group B and p = 0.001 for D126 and D287 Group C) (Fig. 5III).

Discussion:
In this phase I first-in-human clinical trial, we found that vaccination with candidate TB vaccine ChAdOx1 85A was well tolerated Vaccination with ChAdOx1 85A induced Ag85A-specific IFN-c responses. As expected from previous studies, these responses were boosted with MVA85A vaccination, and the direct effect of homologous boosting with ChAdOx1 85A was minimal. AUC analysis of the Ag85A-specific IFN-c ELISpot response 1-24 weeks after vaccination with MVA85A showed no significant difference between Group B and Group C, although both had higher median AUC responses than a previous trial of MVA85A when given alone. We have previously shown that potent Ag85A-specific immune responses were induced by MVA85A boosting of AERAS-402 vaccine in healthy UK adults, the magnitude of these boosted responses in the group that received two doses of AERAS-402 was comparable to those detected in Group C of the present trial (p = 0.176) and to a single dose of MVA85A (p = 0.728) [14,20].
The critical role of IFN-c in control of TB has been reported in humans and animal models and we have shown that vaccineinduced Mycobacteria-specific IFN-c secreting cells are associated with reduced risk of TB disease [21][22][23][24]. ChAdOx1 85A did not enhance PPD IFN-c responses; this might be attributed to the high PPD responses detected at baseline, which are expected in BCGvaccinated individuals. Other cytokines are shown to play a role in protection against TB; blocking TNF-a is reported to be associated with susceptibility to TB [25], IL-2, another Th1 cytokine, induces proliferation and maintenance of effector CD4+ and CD8+ T cells [26] and IL-17 has been associated with protection against TB in mice and humans [27,28]. Production of these cytokines was also induced by ChAdOx1 85A and boosted by MVA85A. Studies in humans and animals have suggested a significant role of CD8 + T cells in control of TB [29][30][31]. Vaccination with ChAdOx1 85A resulted in significant Ag85A-specific IFN-c+ TNF-a+ CD8+ T cells  Red dots indicate median values in each group. The Wilcoxon matched pairs signed rank test was used to detect differences between time points in the same group. Significant differences between groups are as follows: *P 0.05, **P 0.01, ***P 0.001. which were boosted by MVA85A, previously reported to be a poor inducer of CD8+ T cells responses [20]. The responses in subjects boosted with MVA85A were higher than those in the ChAdOx1 85A alone group, reflecting the superior immunogenicity of a prime-boost combination reported for other pathogens [13,16,17,[32][33][34].
Polyfunctional T cells have been shown to play a role in protection against intracellular pathogens and were shown to be induced by MVA85A vaccination [35][36][37]. Here we demonstrate that polyfunctional CD4+ T cells are induced by ChAdOx1 85A vaccination and homologous boosting was required to obtain polyfunctional CD8+ T cell responses, but had minimal effect on the detected polyfunctional CD4+ T cells responses.
Immune responses to viral vectors may potentially modify Ag85A-specific responses [38], to this end we have tested vectorspecific cellular and humoral responses. Low baseline (D0) vector-specific IFN-c responses were detected in volunteers from the 4 study groups (median ELISpot responses of 3 SFC/1 Â 10 6 PBMC for MVA CD4, 4 SFC/1 Â 10 6 PBMC for MVA CD8 of and 102 SFC/1 Â 10 6 PBMC for ChAdOx1). A single dose of ChAdOx1 85A induced ChAdOx1-specific IFN-c responses but were not boosted by homologous vaccination. MVA-specific IFN-c responses were detected following MVA85A vaccination as we have shown previously [14]. The detected cellular anti-vector responses were not associated with the vaccine-induced insert-specific responses.
Although the role of antibodies in control of TB is unclear, some studies have demonstrated a crucial role of antibodies in protection against infection and we have demonstrated that vaccineinduced Ag85A-specific IgG is associated with a reduced risk of TB disease [24,39]. Here, we show that vaccination with ChAdOx1 85A enhances Ag85A-specific IgG responses, which in turn are boosted by MVA85A. IgG antibodies to the vectors were detected following vaccination; however no association between antivector and anti-Ag85A IgG responses is evident.
Whilst it is likely that more than one antigen is needed in a subunit vaccine for protection in genetically diverse human populations, this experimental medicine study demonstrates proof-ofconcept of a prime-boost approach with a novel simian adenoviral vector prime and an MVA boost in BCG-vaccinated adults. Further work is needed to identify novel antigenic targets for inclusion in a multi-antigenic prime-boost vaccination regimen.

Conclusion
This is the first study of the safety and immunogenicity of ChAdOx1 85A in humans. We have shown the vaccine to be well-tolerated when given alone or in combination with MVA85A, and that ChAdOx1 85A induces potent Ag85A specific CD4+ and CD8+ T cell responses which are boosted by MVA85A vaccination.
Financial support statement